Delivery Order SPE2DB20D3103-SPE2DB22FM2F6
Award Date
1/10/22
Potential Completion Date
1/11/22
Potential Value
$21K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $7,696.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a completion date of February 23, 2024. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which serves as a critical supplier of pharmaceutical products and medical supplies to...
This federal contract award, valued at $7,061.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a completion date of January 23, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and Veterans Affairs...
This federal contract award, with ID SPE2DB20D3104|SPE2DB21FW0E5, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,511.36, is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., is the prime contractor for this...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,766.05 Firm Fixed Price contract is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a completion date of March 4, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,292.03, is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract has an ultimate completion date of January 6, 2025 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) between...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,985.44, is for the delivery of HEMABATE 250 MCG/ML ampules. The contract has a completion date of October 2, 2023 and is a Firm Fixed Price Delivery Order. There is no set-aside designation for this award. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a potential value of $5,486.15 and a completion date of January 29, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on February 26, 2025 with a ceiling value of $1,695.80. The contract has a firm fixed price pricing type and an ultimate completion date of February 27, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of HEMABATE 250 MCG/ML ampules. The award has a ceiling value of $2,686.73 and an ultimate completion date of August 9, 2024. The contract is not associated with any set-aside. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, will provide the required medical supplies through this delivery order, which is part of a larger Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of HEMABATE 250 MCG/ML AMPULML, a prescription medication. The firm-fixed-price contract has a ceiling value of $7,484.47 and a period of performance through August 29, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...